Calretinin plasma or serum concentration is higher in patients with MM than healthy people or patients with benign asbestos-related diseases [16,18,19,20] and it could, therefore, also contribute to an earlier non-invasive diagnosis of MM as a circulating biomarker [18]. This evidence concerns the gene CALB2 and Miyoshi myopathy.